Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / REGN - Is Momenta Pharmaceuticals' Stock a Buy?


REGN - Is Momenta Pharmaceuticals' Stock a Buy?

Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treatment of myasthenia gravis (an autoimmune disorder affecting skeletal muscles) in the third quarter of 2020. 

Will the company's pipeline candidates be successful in their clinical trials? Let's see what we can find out. 

Image source: Getty Images.

Continue reading

Stock Information

Company Name: Regeneron Pharmaceuticals Inc.
Stock Symbol: REGN
Market: NASDAQ
Website: regeneron.com

Menu

REGN REGN Quote REGN Short REGN News REGN Articles REGN Message Board
Get REGN Alerts

News, Short Squeeze, Breakout and More Instantly...